ArticleGastroenterology & hepatology2017
New Therapies for Hepatitis C Virus Infection.
Article in Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Prevalence of hepatitis C virus infection in Qatar's resident population based on a national screening campaign.Scientific reports · 2025Article
- Prevalence of hepatitis B and C viruses among migrant workers in Qatar.Scientific reports · 2024Article
- Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.Medicina (Kaunas, Lithuania) · 2023Observational
- Transcriptional Inhibition of MicroRNA miR-122 by Small Molecules Reduces Hepatitis C Virus Replication in Liver Cells.Journal of medicinal chemistry · 2022Article
- Article
- Viral hepatitis: A global burden needs future directions for the management.World journal of gastroenterology · 2022Article
- Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State.Infectious disease reports · 2021Article
- In Vitro Antiviral Activity of Tyrosinase from MushroomPharmaceuticals (Basel, Switzerland) · 2021Article
- Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH).Heliyon · 2021Article
- Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- COVID-19: Characteristics and Therapeutics.Cells · 2021Review
- Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.Drugs in context · 2020Article
- Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?Journal of clinical microbiology · 2019Article
- Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE.Pharmacology research & perspectives · 2019Article
- Use of ModifiedInternational journal of molecular sciences · 2019Article
- Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections.Reviews in medical virology · 2019Review
- Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs.Drug and alcohol review · 2019Article
- Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1.World journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90% of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis. As DAA development continues, more attention will need to be given to special patient populations, specifically to patients who fail treatment due to emerging resistant strains. Considerable challenges yet to be overcome are incremental diagnosis of unidentified patients and linkage to care that is affordable and available to all patients.
Indexed as
Identifiers
28420944PMC5390323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.